At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Lymphoma. Completed, enrolled 66 participants across 50 sites in 13 countries.
Detailed Summary
The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesBrazil, Canada, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Russia, Singapore, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartOct 2016
Primary CompletionJun 2019
Study CompletionNov 2020
TodayJul 2026
First PostedAug 5, 2016
Enrollment StartOct 21, 2016
Primary CompletionJun 11, 2019
Study CompletionNov 24, 2020
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 9.9 years ago
Interventions
Nivolumabdrug